Myriad Genetics, Inc.
MYGN
$7.33
$0.314.42%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.70M | 213.10M | 195.90M | 210.60M | 213.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.70M | 213.10M | 195.90M | 210.60M | 213.30M |
| Cost of Revenue | 61.90M | 61.30M | 61.70M | 59.70M | 63.50M |
| Gross Profit | 143.80M | 151.80M | 134.20M | 150.90M | 149.80M |
| SG&A Expenses | 138.90M | 138.70M | 135.70M | 136.00M | 139.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.00M | 225.60M | 224.90M | 227.90M | 231.10M |
| Operating Income | -23.30M | -12.50M | -29.00M | -17.30M | -17.80M |
| Income Before Tax | -26.20M | -330.60M | -29.40M | -39.10M | -21.20M |
| Income Tax Expenses | 1.20M | -100.00K | -29.30M | 3.40M | 900.00K |
| Earnings from Continuing Operations | -27.40M | -330.50M | -100.00K | -42.50M | -22.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.40M | -330.50M | -100.00K | -42.50M | -22.10M |
| EBIT | -23.30M | -12.50M | -29.00M | -17.30M | -17.80M |
| EBITDA | -10.70M | 1.60M | -14.60M | -2.50M | -2.20M |
| EPS Basic | -0.29 | -3.57 | 0.00 | -0.47 | -0.24 |
| Normalized Basic EPS | -0.18 | -0.09 | -0.20 | -0.10 | -0.13 |
| EPS Diluted | -0.29 | -3.57 | 0.00 | -0.47 | -0.24 |
| Normalized Diluted EPS | -0.18 | -0.09 | -0.20 | -0.10 | -0.13 |
| Average Basic Shares Outstanding | 93.10M | 92.50M | 91.40M | 91.10M | 90.90M |
| Average Diluted Shares Outstanding | 93.10M | 92.50M | 91.40M | 91.10M | 90.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |